Browsing by Author "Barroso, F."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Anti-inflammatory effect of the antidepressant fluvoxamine – a systematic reviewPublication . Ramalho, A.; Carvalho, R.; Barroso, F.; Cruz, A.; Santos, M.Neuroinflammation corresponds to the immune response of the nervous system to an injury, infection or neurodegenerative disease characterized by the activation of resident glial cells, including microglia and astrocytes, the release of cytokines and chemokines and the activation and migration of leukocytes. Evidence suggests that inflammatory cytokines may be a central factor, affecting multiple neuronal pathways and contributing to the development of depression. Supporting this neuroinflammatory theory, several studies have demonstrated the anti-inflammatory effect of various antidepressant drugs [1]. Fluvoxamine is a selective serotonin uptake inhibitor (SSRIs) used manly in the treatment of depression and anxiety disorders. Recent evidence pointed that a fluvoxamine early treatment on SARS-CoV-2-infected subjets fully prevented COVID-19 symptoms [2]. Thus, it seems relevant to explore the anti-inflammatory mechanism of fluvoxamine.
- The involvement of Nrf2 in depression: systematic review of preclinical studiesPublication . Fonseca, D.; Carvalho, R.; Barroso, F.; Cruz, A.; Santos, M.Increased levels of pro-inflammatory cytokines and decreased antioxidant defenses are likely to be linked to the development of depressive symptoms. Nrf2 plays an important role in cellular defense against oxidative stress and binds to ARE, which is located in the promoter region of several phase II antioxidant enzymes and associated stress-responsive enzymes. Reduced Keap1-Nrf2 signaling is implicated in the pathogenesis of mood disorders such as Major Depressive Disorder (MDD).